[1] Weinreb RN, Aung T, Medeiros FA. The pathophysiology and treatment of glaucoma: a review. JAMA. 2014;311:1901–11.
[2] Jampel HD, Frick KD, Janz NK, Wren PA, Musch DC, Rimal R, et al. Depression and mood indicators in newly diagnosed glaucoma patients. Am J Ophthalmol. 2007;144:238–44.
[3] Wang SY, Singh K, Lin SC. Prevalence and predictors of depression among participants with glaucoma in a nationally representative population sample. Am J Ophthalmol. 2012;154:436–44 e2.
[4] Mabuchi F, Yoshimura K, Kashiwagi K, Yamagata Z, Kanba S, Iijima H, et al. Risk factors for anxiety and depression in patients with glaucoma. Br J Ophthalmol. 2012;96:821–5.
[5] Zhou C, Qian S, Wu P, Qiu C. Anxiety and depression in Chinese patients with glaucoma: sociodemographic, clinical, and self-reported correlates. J Psychosom Res. 2013;75:75–82.
[6] Logean E, Dalimier E, Dainty C. Measured double-pass intensity point-spread function after adaptive optics correction of ocular aberrations. Opt Express. 2008;16:17348–57.
[7] Zhang Y, Zheng L, Bian A, Zhou Q. IOP measurement in silicone oil tamponade eyes by Corvis ST tonometer, Goldmann applanation tonometry and non-contact tonometry. Int Ophthalmol. 2018;38:697–703.
[8] Wang YJ, Yang YN, Huang LY, Wang B, Han YC, Yan JB. Optical Quality and Related Factors in Ocular Hypertension: Preliminary Study. J Ophthalmol. 2016;2016:3071036.
[9] Liu L, Wang Y, Liu J, Liu W. Retinal-image quality and contrast sensitivity function in eyes with epiretinal membrane: a cross-sectional observational clinical study. BMC Ophthalmol. 2018;18:290.
[10] Lee K, Sohn J, Choi JG, Chung SK. Optical quality in central serous chorioretinopathy. Invest Ophthalmol Vis Sci. 2014;55:8598–603.
[11] Hyman LG, Komaroff E, Heijl A, Bengtsson B, Leske MC, Early Manifest Glaucoma Trial G. Treatment and vision-related quality of life in the early manifest glaucoma trial. Ophthalmology. 2005;112:1505–13.
[12] Gedde SJ, Schiffman JC, Feuer WJ, Parrish RK, 2nd, Heuer DK, Brandt JD, et al. The tube versus trabeculectomy study: design and baseline characteristics of study patients. Am J Ophthalmol. 2005;140:275–87.
[13] McKean-Cowdin R, Wang Y, Wu J, Azen SP, Varma R, Los Angeles Latino Eye Study G. Impact of visual field loss on health-related quality of life in glaucoma: the Los Angeles Latino Eye Study. Ophthalmology. 2008;115:941–8 e1.
[14] Gracitelli CP, Abe RY, Tatham AJ, Rosen PN, Zangwill LM, Boer ER, et al. Association between progressive retinal nerve fiber layer loss and longitudinal change in quality of life in glaucoma. JAMA Ophthalmol. 2015;133:384–90.
[15] Gutierrez P, Wilson MR, Johnson C, Gordon M, Cioffi GA, Ritch R, et al. Influence of glaucomatous visual field loss on health-related quality of life. Arch Ophthalmol. 1997;115:777–84.
[16] van Gestel A, Webers CA, Beckers HJ, van Dongen MC, Severens JL, Hendrikse F, et al. The relationship between visual field loss in glaucoma and health-related quality-of-life. Eye (Lond). 2010;24:1759–69.
[17] Lisboa R, Chun YS, Zangwill LM, Weinreb RN, Rosen PN, Liebmann JM, et al. Association between rates of binocular visual field loss and vision-related quality of life in patients with glaucoma. JAMA Ophthalmol. 2013;131:486–94.
[18] Jampel HD, Schwartz A, Pollack I, Abrams D, Weiss H, Miller R. Glaucoma patients’ assessment of their visual function and quality of life. J Glaucoma. 2002;11:154–63.